Riyadh, Saudi Arabia, March 02, 2021 - Shanghai MicroPort Medical (Group) Co. Ltd. (MicroPort®) a subsidiary of MicroPort Scientific Corporation (00853.HK), recently received registration approval from the Saudi Food and Drug Authority for four of its proprietary products. These include Firehawk® Rapamycin Target Eluting Coronary Stent System (Firehawk®), Firehawk Liberty™ Rapamycin Target Eluting Coronary Stent System (Firehawk Liberty™), Firefighter™ PTCA Balloon Catheter (Firefighter™), and Firefighter™ NC PTCA Balloon Catheter (Firefighter™ NC).
Firehawk® is a drug-eluting stent (DES) with grooved strutsand a precision targeting drug-release patent technology. Its hair-thin, dense CoCr alloy struts contain nearly 600 grooves through which the drug is administered using fully automated 3D printing. Firehawk® combines the merits of bare metal and drug-eluting stents, ensuring the same clinical efficacy, yet with a significantly lower drug loading.
While retaining some features of Firehawk® Stent - such as targeted drug-release - Firehawk Liberty™, the latest generation of the Firehawk® line, uses an innovative stent balloon technology to optimize expansion performance, offering better crossability, traceability and pushability, thus further optimizing the crossability and vessel wall apposition.
Following its predecessor, Foxtrot® NC, Firefighter™ has a minimal profile compare with competitor products of the same size and is made of flexible materials, enabling it to cross stenosis and tortuous lesions multiple times. Being able to accommodate two balloon catheters in a 5F introducer catheter despite its extremely small size, it allows surgeons to perform complex maneuvers such as balloon-stent kissing.Firefighter™ NC is a new generation of high-pressure resistant and rapid exchange balloon dilatation catheters following its predecessor, Foxtrot™ NC. Its hydrophilic polymer outer coating reduces friction when in contact with water during surgery, thereby safely facilitating catheter delivery into and across lesions. It is suitable for balloon dilatation of stenoses in coronary tracts or coronary bypass bridges to improve myocardial perfusion, and can also be used in post-balloon dilatation of stents after their implantation.
The materials used in this product are more flexible than many competing products.
It is expected that the marketing approval in Saudi Arabia will further expand the company’s global presence, while MicroPort® continues to grow within the local market to provide quality and integrated solutions for patients and doctors across the country.